What one share of Kazia Therapeutics Limited. holds
The ongoing principal business of the Company has been pharmaceutical drug development. The Company is an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications.
Kazia Therapeutics Limited.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-06-30; the balance sheet is as of 2025-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.24 |
| Dividends | $0.00 |
| Cash and investments | $0.04 |
| Book value | −$0.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$1.15 | — | — | — | $1.03 |
| 2021 | — | −$0.53 | — | — | — | $2.14 |
| 2022 | — | −$1.37 | — | — | — | $0.91 |
| 2023 | — | −$0.75 | — | — | — | $0.35 |
| 2024 | — | −$0.67 | — | — | — | −$0.20 |
| 2025 | $0.00 | −$0.24 | — | — | — | −$0.07 |
Common questions about Kazia Therapeutics Limited.
How much does one share of Kazia Therapeutics Limited. earn?
Over its latest fiscal year, Kazia Therapeutics Limited. lost $0.24 for each share on $0.00 of sales.
Does Kazia Therapeutics Limited. pay a dividend?
Kazia Therapeutics Limited. didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Kazia Therapeutics Limited.’s book value per share?
Kazia Therapeutics Limited.’s book value is negative (−$0.07 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2025.
How much cash and debt does each share of Kazia Therapeutics Limited. have?
Each share of Kazia Therapeutics Limited. has $0.04 of cash and investments, as of June 30, 2025.
Has Kazia Therapeutics Limited. bought back shares?
Kazia Therapeutics Limited.’s share count rose about 650% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.